Skip to main content
Clinical Trials/JPRN-UMIN000008023
JPRN-UMIN000008023
Recruiting
Phase 2

Phase II multicenter trial of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant chemotherapy by irrinotecan hydrochloride and nedaplatin for the patients with stage Ib2-IIb bulky cervical cancer (tumor diameter > 4 cm): OGSK_KCOG-G1201 - NACRAC study

The Obstetrical and Gynecological Society of Kinki District Japan and the Kansai Clinical Oncology Group0 sites68 target enrollmentMay 28, 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
The Obstetrical and Gynecological Society of Kinki District Japan and the Kansai Clinical Oncology Group
Enrollment
68
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 28, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
The Obstetrical and Gynecological Society of Kinki District Japan and the Kansai Clinical Oncology Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients with an active or uncontrolled infection, 2\. Patients with a serious complications (cardiac disease, poorly controlled diabetes mellitus, malignant hypertension and bleeding tendency), 3\. Patients with other malignancies, 4\. Patients with interstitial pneumonitis, 5\. Patients with massive pleural effusion and/or ascites, 6\. Patients with unstable angina or those who have had a myocardial infarction within the past six months, 7\. Patients with medical contraindications to irrinotecan hydrochloride and nedaplatin, 8\. Patients with severe diarrhea, 9\. Patients with bowel obstruction, 10\. Patients who are pregnant or lactating, 11\. Patients with severe drug allergy, 12\. Patients whose circumstances at the time of entry onto the protocol would not permit completion of study required follow\-up, 13\. Patients with HBsAg positivity

Outcomes

Primary Outcomes

Not specified

Similar Trials